VolitionRx's (VNRX) "Buy" Rating Reaffirmed at D. Boral Capital

VolitionRx (NYSE:VNRX - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $5.00 target price on the stock.

Several other research analysts have also recently issued reports on VNRX. StockNews.com assumed coverage on VolitionRx in a research report on Tuesday. They set a "sell" rating on the stock. Benchmark reaffirmed a "hold" rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Trading Down 0.9 %

Shares of NYSE:VNRX traded down $0.01 during mid-day trading on Tuesday, hitting $0.61. 60,973 shares of the company traded hands, compared to its average volume of 105,729. The stock has a market cap of $56.06 million, a P/E ratio of -1.68 and a beta of 1.09. VolitionRx has a 12-month low of $0.43 and a 12-month high of $1.10. The stock has a 50-day moving average price of $0.61 and a two-hundred day moving average price of $0.65.

Insider Buying and Selling

In other news, Director Guy Archibald Innes bought 174,764 shares of the stock in a transaction on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the purchase, the director now directly owns 617,085 shares in the company, valued at $351,738.45. This represents a 39.51 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Cameron John Reynolds bought 139,811 shares of the stock in a transaction on Monday, December 9th. The stock was purchased at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the completion of the purchase, the chief executive officer now owns 2,117,404 shares of the company's stock, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 358,266 shares of company stock worth $204,212. 12.80% of the stock is owned by company insiders.

Remove Ads

Institutional Trading of VolitionRx

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in shares of VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company's stock valued at $439,000 after buying an additional 95,900 shares during the period. Millennium Management LLC bought a new stake in shares of VolitionRx in the fourth quarter valued at $36,000. Northern Trust Corp raised its stake in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after purchasing an additional 28,579 shares during the period. Lagoda Investment Management L.P. raised its stake in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after purchasing an additional 1,481,000 shares during the period. Finally, Two Sigma Securities LLC bought a new stake in shares of VolitionRx during the 4th quarter valued at $29,000. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.